.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Teva
Chinese Patent Office
Novartis
Healthtrust
Colorcon
Dow
Chubb
Queensland Health

Generated: September 25, 2017

DrugPatentWatch Database Preview

Organon Sub Merck Company Profile

« Back to Dashboard

What is the competitive landscape for ORGANON SUB MERCK, and when can generic versions of ORGANON SUB MERCK drugs launch?

ORGANON SUB MERCK has one approved drug.

There are three US patents protecting ORGANON SUB MERCK drugs.

There are fifty-two patent family members on ORGANON SUB MERCK drugs in twenty-nine countries.

Summary for Applicant: Organon Sub Merck

Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Organon Sub Merck

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Organon Sub Merck Drugs

Country Document Number Estimated Expiration
Japan2003507335► Subscribe
Hungary227451► Subscribe
China1241576► Subscribe
Canada2380920► Subscribe
China1188428► Subscribe
Norway328790► Subscribe
Australia776536► Subscribe
MexicoPA02004940► Subscribe
Israel149423► Subscribe
Slovakia7262002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Organon Sub Merck Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C031/2008Ireland► SubscribeSPC031/2008: 20090428, EXPIRES: 20230724
C/GB08/057United Kingdom► SubscribePRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725
2009 00002Denmark► Subscribe
47/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTR√ĄGLICHES SALZ HIERVON
1259550/01Switzerland► SubscribeFUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
501Luxembourg► Subscribe91501, EXPIRES: 20230725
0Finland► Subscribe
0356Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Accenture
Fuji
Boehringer Ingelheim
Colorcon
Queensland Health
Citi
Baxter
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot